Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.
Identifieur interne : 001215 ( Main/Corpus ); précédent : 001214; suivant : 001216Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.
Auteurs : Alimuddin Zumla ; Fu-Sheng Wang ; Giuseppe Ippolito ; Nicola Petrosillo ; Chiara Agrati ; Esam I. Azhar ; Chao Chang ; Sherif A. El-Kafrawy ; Mohamed Osman ; Laurence Zitvogel ; Peter R. Galle ; Franco Locatelli ; Ellen Gorman ; Carlos Cordon-Cardo ; Cecilia O'Kane ; Danny Mcauley ; Markus MaeurerSource :
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [ 1878-3511 ] ; 2020.
English descriptors
- KwdEn :
- Betacoronavirus (MeSH), Clinical Trials as Topic (MeSH), Consensus (MeSH), Coronavirus Infections (immunology), Coronavirus Infections (mortality), Coronavirus Infections (pathology), Coronavirus Infections (therapy), Humans (MeSH), Mesenchymal Stem Cell Transplantation (MeSH), Morbidity (MeSH), Pandemics (MeSH), Pneumonia, Viral (immunology), Pneumonia, Viral (mortality), Pneumonia, Viral (pathology), Pneumonia, Viral (therapy).
- MESH :
- immunology : Coronavirus Infections, Pneumonia, Viral.
- mortality : Coronavirus Infections, Pneumonia, Viral.
- pathology : Coronavirus Infections, Pneumonia, Viral.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Clinical Trials as Topic, Consensus, Humans, Mesenchymal Stem Cell Transplantation, Morbidity, Pandemics.
Abstract
As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations. A paradigm shift is underway from the current focus of drug development targeting the pathogen, to advancing cellular Host-Directed Therapies (HDTs) for tackling the aberrant host immune and inflammatory responses which underlie the pathogenesis of SARS-CoV-2 and high COVID-19 mortality rates. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. Currently, the ClinicalTrials.gov and the WHO Clinical Trials Registry Platform (WHO ICTRP) report a combined 28 trials exploring the potential of MSCs or their products for treatment of COVID-19. MSCs should also be trialed for treatment of other circulating WHO priority Blueprint pathogens such as MERS-CoV which causes upto 34% mortality rates. It's about time funding agencies invested more into development MSCs per se, and also for a range of other HDTs, in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 death rates and preventing long-term functional disability in those who survive disease.
DOI: 10.1016/j.ijid.2020.05.040
PubMed: 32425638
PubMed Central: PMC7231497
Links to Exploration step
pubmed:32425638Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.</title><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name><affiliation><nlm:affiliation>Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Fu Sheng" sort="Wang, Fu Sheng" uniqKey="Wang F" first="Fu-Sheng" last="Wang">Fu-Sheng Wang</name><affiliation><nlm:affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: fswang302@163.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ippolito, Giuseppe" sort="Ippolito, Giuseppe" uniqKey="Ippolito G" first="Giuseppe" last="Ippolito">Giuseppe Ippolito</name><affiliation><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: giuseppe.ippolito@inmi.it.</nlm:affiliation></affiliation></author><author><name sortKey="Petrosillo, Nicola" sort="Petrosillo, Nicola" uniqKey="Petrosillo N" first="Nicola" last="Petrosillo">Nicola Petrosillo</name><affiliation><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: nicola.petrosillo@inmi.it.</nlm:affiliation></affiliation></author><author><name sortKey="Agrati, Chiara" sort="Agrati, Chiara" uniqKey="Agrati C" first="Chiara" last="Agrati">Chiara Agrati</name><affiliation><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: Chiara.Agrati@inmi.it.</nlm:affiliation></affiliation></author><author><name sortKey="Azhar, Esam I" sort="Azhar, Esam I" uniqKey="Azhar E" first="Esam I" last="Azhar">Esam I. Azhar</name><affiliation><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: eazhar@kau.edu.sa.</nlm:affiliation></affiliation></author><author><name sortKey="Chang, Chao" sort="Chang, Chao" uniqKey="Chang C" first="Chao" last="Chang">Chao Chang</name><affiliation><nlm:affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: zhangch302@163.com.</nlm:affiliation></affiliation></author><author><name sortKey="El Kafrawy, Sherif A" sort="El Kafrawy, Sherif A" uniqKey="El Kafrawy S" first="Sherif A" last="El-Kafrawy">Sherif A. El-Kafrawy</name><affiliation><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: saelkfrawy@kau.edu.sa.</nlm:affiliation></affiliation></author><author><name sortKey="Osman, Mohamed" sort="Osman, Mohamed" uniqKey="Osman M" first="Mohamed" last="Osman">Mohamed Osman</name><affiliation><nlm:affiliation>Emerging and Re-Emerging Diseases, University of Khartoum, Sudan and York Biomedical Research Institute, University of York, United Kingdom. Electronic address: mohamed.osman@york.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation><nlm:affiliation>Gustave Roussy Cancer Center (GRCC), U1015 INSERM, University Paris Saclay Villejuif Cedex, France. Electronic address: laurence.zitvogel@orange.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Galle, Peter R" sort="Galle, Peter R" uniqKey="Galle P" first="Peter R" last="Galle">Peter R. Galle</name><affiliation><nlm:affiliation>Medical Clinic, University Medical Center Mainz, Germany. Electronic address: Galle@uni-mainz.de.</nlm:affiliation></affiliation></author><author><name sortKey="Locatelli, Franco" sort="Locatelli, Franco" uniqKey="Locatelli F" first="Franco" last="Locatelli">Franco Locatelli</name><affiliation><nlm:affiliation>Dept of Pediatric Hematology and Oncology, IRCCS Ospedale Bambino Gesu, and Sapienza, University of Rome, Italy. Electronic address: franco.locatelli@opbg.net.</nlm:affiliation></affiliation></author><author><name sortKey="Gorman, Ellen" sort="Gorman, Ellen" uniqKey="Gorman E" first="Ellen" last="Gorman">Ellen Gorman</name><affiliation><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: egorman03@qub.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Cordon Cardo, Carlos" sort="Cordon Cardo, Carlos" uniqKey="Cordon Cardo C" first="Carlos" last="Cordon-Cardo">Carlos Cordon-Cardo</name><affiliation><nlm:affiliation>Dept of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: carlos.cordon-cardo@mssm.edu.</nlm:affiliation></affiliation></author><author><name sortKey="O Kane, Cecilia" sort="O Kane, Cecilia" uniqKey="O Kane C" first="Cecilia" last="O'Kane">Cecilia O'Kane</name><affiliation><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: c.okane@qub.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Mcauley, Danny" sort="Mcauley, Danny" uniqKey="Mcauley D" first="Danny" last="Mcauley">Danny Mcauley</name><affiliation><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: d.f.mcauley@qub.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name><affiliation><nlm:affiliation>Medical Clinic, University Medical Center Mainz, Germany; Champalimaud Centre for the Unknown, Lisbon, Portugal. Electronic address: markus.maeurer@fundacaochampalimaud.pt.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32425638</idno><idno type="pmid">32425638</idno><idno type="doi">10.1016/j.ijid.2020.05.040</idno><idno type="pmc">PMC7231497</idno><idno type="wicri:Area/Main/Corpus">001215</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001215</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.</title><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name><affiliation><nlm:affiliation>Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Fu Sheng" sort="Wang, Fu Sheng" uniqKey="Wang F" first="Fu-Sheng" last="Wang">Fu-Sheng Wang</name><affiliation><nlm:affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: fswang302@163.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ippolito, Giuseppe" sort="Ippolito, Giuseppe" uniqKey="Ippolito G" first="Giuseppe" last="Ippolito">Giuseppe Ippolito</name><affiliation><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: giuseppe.ippolito@inmi.it.</nlm:affiliation></affiliation></author><author><name sortKey="Petrosillo, Nicola" sort="Petrosillo, Nicola" uniqKey="Petrosillo N" first="Nicola" last="Petrosillo">Nicola Petrosillo</name><affiliation><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: nicola.petrosillo@inmi.it.</nlm:affiliation></affiliation></author><author><name sortKey="Agrati, Chiara" sort="Agrati, Chiara" uniqKey="Agrati C" first="Chiara" last="Agrati">Chiara Agrati</name><affiliation><nlm:affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: Chiara.Agrati@inmi.it.</nlm:affiliation></affiliation></author><author><name sortKey="Azhar, Esam I" sort="Azhar, Esam I" uniqKey="Azhar E" first="Esam I" last="Azhar">Esam I. Azhar</name><affiliation><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: eazhar@kau.edu.sa.</nlm:affiliation></affiliation></author><author><name sortKey="Chang, Chao" sort="Chang, Chao" uniqKey="Chang C" first="Chao" last="Chang">Chao Chang</name><affiliation><nlm:affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: zhangch302@163.com.</nlm:affiliation></affiliation></author><author><name sortKey="El Kafrawy, Sherif A" sort="El Kafrawy, Sherif A" uniqKey="El Kafrawy S" first="Sherif A" last="El-Kafrawy">Sherif A. El-Kafrawy</name><affiliation><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: saelkfrawy@kau.edu.sa.</nlm:affiliation></affiliation></author><author><name sortKey="Osman, Mohamed" sort="Osman, Mohamed" uniqKey="Osman M" first="Mohamed" last="Osman">Mohamed Osman</name><affiliation><nlm:affiliation>Emerging and Re-Emerging Diseases, University of Khartoum, Sudan and York Biomedical Research Institute, University of York, United Kingdom. Electronic address: mohamed.osman@york.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation><nlm:affiliation>Gustave Roussy Cancer Center (GRCC), U1015 INSERM, University Paris Saclay Villejuif Cedex, France. Electronic address: laurence.zitvogel@orange.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Galle, Peter R" sort="Galle, Peter R" uniqKey="Galle P" first="Peter R" last="Galle">Peter R. Galle</name><affiliation><nlm:affiliation>Medical Clinic, University Medical Center Mainz, Germany. Electronic address: Galle@uni-mainz.de.</nlm:affiliation></affiliation></author><author><name sortKey="Locatelli, Franco" sort="Locatelli, Franco" uniqKey="Locatelli F" first="Franco" last="Locatelli">Franco Locatelli</name><affiliation><nlm:affiliation>Dept of Pediatric Hematology and Oncology, IRCCS Ospedale Bambino Gesu, and Sapienza, University of Rome, Italy. Electronic address: franco.locatelli@opbg.net.</nlm:affiliation></affiliation></author><author><name sortKey="Gorman, Ellen" sort="Gorman, Ellen" uniqKey="Gorman E" first="Ellen" last="Gorman">Ellen Gorman</name><affiliation><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: egorman03@qub.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Cordon Cardo, Carlos" sort="Cordon Cardo, Carlos" uniqKey="Cordon Cardo C" first="Carlos" last="Cordon-Cardo">Carlos Cordon-Cardo</name><affiliation><nlm:affiliation>Dept of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: carlos.cordon-cardo@mssm.edu.</nlm:affiliation></affiliation></author><author><name sortKey="O Kane, Cecilia" sort="O Kane, Cecilia" uniqKey="O Kane C" first="Cecilia" last="O'Kane">Cecilia O'Kane</name><affiliation><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: c.okane@qub.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Mcauley, Danny" sort="Mcauley, Danny" uniqKey="Mcauley D" first="Danny" last="Mcauley">Danny Mcauley</name><affiliation><nlm:affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: d.f.mcauley@qub.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name><affiliation><nlm:affiliation>Medical Clinic, University Medical Center Mainz, Germany; Champalimaud Centre for the Unknown, Lisbon, Portugal. Electronic address: markus.maeurer@fundacaochampalimaud.pt.</nlm:affiliation></affiliation></author></analytic><series><title level="j">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</title><idno type="eISSN">1878-3511</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term><term>Clinical Trials as Topic (MeSH)</term><term>Consensus (MeSH)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (mortality)</term><term>Coronavirus Infections (pathology)</term><term>Coronavirus Infections (therapy)</term><term>Humans (MeSH)</term><term>Mesenchymal Stem Cell Transplantation (MeSH)</term><term>Morbidity (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (mortality)</term><term>Pneumonia, Viral (pathology)</term><term>Pneumonia, Viral (therapy)</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Clinical Trials as Topic</term><term>Consensus</term><term>Humans</term><term>Mesenchymal Stem Cell Transplantation</term><term>Morbidity</term><term>Pandemics</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations. A paradigm shift is underway from the current focus of drug development targeting the pathogen, to advancing cellular Host-Directed Therapies (HDTs) for tackling the aberrant host immune and inflammatory responses which underlie the pathogenesis of SARS-CoV-2 and high COVID-19 mortality rates. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. Currently, the ClinicalTrials.gov and the WHO Clinical Trials Registry Platform (WHO ICTRP) report a combined 28 trials exploring the potential of MSCs or their products for treatment of COVID-19. MSCs should also be trialed for treatment of other circulating WHO priority Blueprint pathogens such as MERS-CoV which causes upto 34% mortality rates. It's about time funding agencies invested more into development MSCs per se, and also for a range of other HDTs, in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 death rates and preventing long-term functional disability in those who survive disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32425638</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int. J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.</ArticleTitle><Pagination><MedlinePgn>431-439</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(20)30347-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2020.05.040</ELocationID><Abstract><AbstractText>As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations. A paradigm shift is underway from the current focus of drug development targeting the pathogen, to advancing cellular Host-Directed Therapies (HDTs) for tackling the aberrant host immune and inflammatory responses which underlie the pathogenesis of SARS-CoV-2 and high COVID-19 mortality rates. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. Currently, the ClinicalTrials.gov and the WHO Clinical Trials Registry Platform (WHO ICTRP) report a combined 28 trials exploring the potential of MSCs or their products for treatment of COVID-19. MSCs should also be trialed for treatment of other circulating WHO priority Blueprint pathogens such as MERS-CoV which causes upto 34% mortality rates. It's about time funding agencies invested more into development MSCs per se, and also for a range of other HDTs, in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 death rates and preventing long-term functional disability in those who survive disease.</AbstractText><CopyrightInformation>Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zumla</LastName><ForeName>Alimuddin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fu-Sheng</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: fswang302@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ippolito</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: giuseppe.ippolito@inmi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrosillo</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: nicola.petrosillo@inmi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrati</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: Chiara.Agrati@inmi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azhar</LastName><ForeName>Esam I</ForeName><Initials>EI</Initials><AffiliationInfo><Affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: eazhar@kau.edu.sa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: zhangch302@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Kafrawy</LastName><ForeName>Sherif A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: saelkfrawy@kau.edu.sa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osman</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Emerging and Re-Emerging Diseases, University of Khartoum, Sudan and York Biomedical Research Institute, University of York, United Kingdom. Electronic address: mohamed.osman@york.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zitvogel</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gustave Roussy Cancer Center (GRCC), U1015 INSERM, University Paris Saclay Villejuif Cedex, France. Electronic address: laurence.zitvogel@orange.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galle</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Medical Clinic, University Medical Center Mainz, Germany. Electronic address: Galle@uni-mainz.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locatelli</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dept of Pediatric Hematology and Oncology, IRCCS Ospedale Bambino Gesu, and Sapienza, University of Rome, Italy. Electronic address: franco.locatelli@opbg.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorman</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: egorman03@qub.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordon-Cardo</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dept of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: carlos.cordon-cardo@mssm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Kane</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: c.okane@qub.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAuley</LastName><ForeName>Danny</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: d.f.mcauley@qub.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeurer</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Clinic, University Medical Center Mainz, Germany; Champalimaud Centre for the Unknown, Lisbon, Portugal. Electronic address: markus.maeurer@fundacaochampalimaud.pt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009017" MajorTopicYN="N">Morbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32425638</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2020.05.040</ArticleId><ArticleId IdType="pii">S1201-9712(20)30347-7</ArticleId><ArticleId IdType="pmc">PMC7231497</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001215 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001215 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32425638
|texte= Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32425638" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |